Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model

Nanomedicine

Volumn 6, Issue 10, 2011, Pages 1669-1682

  Scheinman, Robert I ^a   Trivedi, Ruchit ^a,b   Vermillion, Sam ^c   Kompella, Uday B ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE

Author keywords

macrophage; nanoparticle; rheumatoid arthritis; siRNA; STAT1

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID POLYGLACTIN STAT1 PROTEIN SMALL INTERFERING RNA; INTERLEUKIN 10; MESSENGER RNA; NANOPARTICLE; POLYGLACTIN; SMALL INTERFERING RNA; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GENE SILENCING; GENE THERAPY; INTERLEUKIN-10; LACTIC ACID; MACROPHAGES; MICE; NANOPARTICLES; OLIGOPEPTIDES; POLYGLYCOLIC ACID; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR;

EID: 82455217419     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.90     Document Type: Article

References (44)

1. McInnes IB, Liew FY. Cytokine networks towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1(1), 31-39 (2005).
2. Waldenburger JM, Firestein GS. Rheumatoid Arthritis Epidemiology Pathology and Pathogenesis. In: Primer on the Rheumatic Diseases. Klippel JH (Ed.). Springer, NY, USA, 122-132 (2008).
3. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum. Dis. Clin. North Am. 36(2), 385-404 (2010).
4. Pap T, Distler O. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum. 52(5), 1346-1348 (2005). (Pubitemid 40663924)
5. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 22(3), 299-306 (2010).
6. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 233(1), 301-312 (2010).
7. Lu JM, Wang X, Marin-Muller C et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9(4), 325-341 (2009).
8. Singh SR, Grossniklaus HE, Kang SJ et a l. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16(5), 645-659 (2009).
9. Sundaram S, Trivedi R, Durairaj C et al. Targeted drug and gene delivery systems for lung cancer therapy Clin. Cancer Res. 15(23), 7299-7308 (2009).
10. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J. Pharm. Pharmacol. 55(9), 1199-1206 (2003). (Pubitemid 37180005)
11. Brandhonneur N, Chevanne F, Vie V et al. Specifc and non-specifc phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur. J. Pharm. Sci. 36(4-5), 474-485 (2009).
12. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19(3), 289-295 (2007). (Pubitemid 46597469)
13. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in infammatory and autoimmune diseases. Arthritis Rheum. 60(5), 1210-1221 (2009).
14. Ohashi K, Kabasawa T, Ozeki T, Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fuid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 135(1), 19-24 (2009).
15. Cohen-Sela E, Teitlboim S, Chorny M et al. Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity. J. Pharm. Sci. 98(4), 1452-1462 (2009).
16. Khaled KA, Sarhan HA, Ibrahim MA, Ali AH, Naguib YW. Prednisolone-loaded PLGA microspheres. In vitro characterization and in vivo application in adjuvant-induced arthritis in mice. AAPS PharmSciTech. 11(2), 859-869 (2010).
17. Puebla P, Pastoriza P, Barcia E, Fernandez-Carballido A. PEG-derivative effectively modifes the characteristics of indomethacin-PLGA microspheres destined to intra-articular administration. J. Microencapsul. 22(7), 793-808 (2005). (Pubitemid 43158199)
18. Horisawa E, Kubota K, Tuboi I et al. Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm. Res. 19(2), 132-139 (2002). (Pubitemid 34165397)
19. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 226, 41-56 (2008).
20. Zhou F. Molecular mechanisms of IFN-g to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28(3-4), 239-260 (2009).
21. Williams-Skipp C, Raman T, Valuck RJ, Watkins H, Palmer BE, Scheinman RI. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum. 60(2), 408-418 (2009).
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162(1), 156-159 (1987). (Pubitemid 17064313)
23. Bejjani RA, Benezra D, Cohen H et al Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11, 124-132 (2005). (Pubitemid 41358300)
24. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modifed with monoclonal antibody. J. Control. Release 120(1-2), 18-26 (2007). (Pubitemid 46874614)
25. Butler DM, Malfait AM, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. 29(7), 2205-2212 (1999). (Pubitemid 29313095)
26. Kliwinski C, Kukral D, Postelnek J et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J. Autoimmun. 25(3), 165-171 (2005). (Pubitemid 41654460)
27. Liang B, Song Z, Wu B et al. Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis. J. Infamm. (Lond.) 6, 10 (2009).
28. Setoguchi C, Tsuji F, Katsuta O, Okamoto M, Aono H. Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model. Mod. Rheumatol. 20(4), 381-388(2010).
29. Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN. Evaluation of TNF-a and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-a/anti-CD4 therapy. J. Immunol. 165(12), 7240-7245 (2000). (Pubitemid 32001202)
30. Yoshida H, Hashizume M, Mihara M. IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis. Rheumatol. Int. 31(1), 127-131 (2010).
31. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 339(1), 269-280 (2010).
32. Whalen JD, Lechman EL, Carlos CA et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J. Immunol. 162(6), 3625-3632 (1999). (Pubitemid 29313617)
33. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 52(5), 1595-1603 (2005). (Pubitemid 40663952)
34. Amital A, Shitrit D, Adir Y. The lung in rheumatoid arthritis. Presse Med. 40(1 Pt 2), e31-e48 (2011).
35. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-g: implications for immune responses and autoimmune diseases. Immunity 31(4), 539-550 (2009).
36. + regulatory T cells in autoimmune arthritis. Immunol. Rev. 233(1), 97-111 (2010).
37. Page CE, Smale S, Carty SM et al. Interferon-g inhibits interleukin-1b-induced matrix metalloproteinase production by synovial fbroblasts and protects articular cartilage in early arthritis. Arthritis Res. Ther. 12(2), R49 (2010).
38. Gaffen SL. The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr. Rheumatol. Rep. 11(5), 365-370 (2009).
39. Van Den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5(10), 549-553 (2009).
40. Kleinman ME, Yamada K, Takeda A et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452(7187), 591-597 (2008). (Pubitemid 351483358)
41. Agarwal S, Misra R, Aggarwal A. Induction of metalloproteinases expression by TLR ligands in human fbroblast like synoviocytes from juvenile idiopathic arthritis patients. Indian J. Med. Res. 131, 771-779 (2010).
42. Alsaleh G, Sparsa L, Chatelus E et al. Innate immunity triggers IL-32 expression by fbroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res. Ther. 12(4), R135 (2010).
43. Meng L, Zhu W, Jiang C et al. Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res. Ther. 12(3), R103 (2010).
44. Moon SJ, Park MK, Oh HJ et al. Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fbroblasts. Korean J. Intern. Med. 25(4), 429-435 (2010).